Quantcast

VenatoRx Pharmaceuticals to Present at ASM Microbe 2019

MALVERN, Pa.–(BUSINESS WIRE)–#ASMMicrobe2019VenatoRx
Pharmaceuticals
will present ten posters featuring its two
development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145,
at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. VenatoRx
will also present an overview if its antibacterial agents portfolio
during the Pharma Pipeline Update, concentrating on its orally
bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents
Discovery Summary Session.

VenatoRx’s presentations at ASM Microbe will take place as follows:

— Friday, June 21, 2019 —

Session 020
New
Agents Discovery Summary Session: Early New Antimicrobial Agents

Title: Orally Bioavailable Beta-lactamase Inhibitor VNRX-7145
Time:
9:50am – 10:10am PT
Presenter: Daniel C. Pevear, Ph.D., Senior Vice
President, Biology, VenatoRx Pharmaceuticals
Location: 207/208 South

Session S107
Pharma
Pipeline Update: Part I

Title: VenatoRx Pipeline
Time: 3:03pm – 3:14pm PT
Presenter:
Christopher J. Burns, Ph.D., President and CEO, VenatoRx Pharmaceuticals
Location:
AAR Track Hub (Booth 5053) – Learn – Exhibit and Poster Hall

— Sunday, June 23, 2019 —

Session P588
AAR08 – New
Antimicrobial Agents (pre-Phase 2): Early Beta-Lactams and
Beta-Lactamase Inhibitor Combinations

Poster Presentation |
11:00am – 1:00pm PT
Location: Exhibit and Poster Hall

  • SUNDAY – AAR-719 — Rescue of Ceftibuten Activity by the Oral
    β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing
    Class A, C and/or D β-Lactamases.
    K.J. John, C.L. Chatwin,
    J.C. Hamrick, G. Moeck, D.C. Pevear.
  • SUNDAY – AAR-720 — The Orally Bioavailable Beta-Lactamase
    Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten
    against Enterobacteriaceae Expressing Ambler Class A, C, and/or D
    Enzymes.
    J.C. Hamrick, C.L. Chatwin, K.J. John, G. Moeck, L.
    Xerri, D.C. Pevear.
  • SUNDAY – AAR-721 — In Vitro Activity of Ceftibuten in
    Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates
    Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin.
    M.
    Hackel, D. Sahm.
  • SUNDAY – AAR-722 — Antimicrobial Activity of Cefepime in
    Combination with VNRX-5133 against a Global 2018 Surveillance
    Collection of Pseudomonas aeruginosa.
    M. Hackel, D. Sahm.
  • SUNDAY – AAR-723 — Synergy/Antagonism of
    Ceftibuten/VNRX-7145 in Combination with Other Commonly Used
    Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic
    Bacteria, and Yeast.
    C.L. Chatwin, K.J. John, J.C. Hamrick, C.J.
    Burns, D.C. Pevear, G. Moeck.
  • SUNDAY – AAR-724 In Vitro Permeability and
    Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145
    across Species.
    R.E. Trout, C.L. Chatwin, L. McLaughlin, J.C.
    Hamrick, G. Moeck, D.C. Pevear.
  • SUNDAY – AAR-726 — Efficacy of Ceftibuten + VNRX-7145 a
    Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a
    Murine UTI Mode.
    M.E. Pulse, W. J. Weiss, P. Nguyen, D. Valtierra,
    K. Peterson, K. Carter, G. Moeck, R.E. Trout, J. Hamrick, D.C. Pevear.
  • SUNDAY – AAR-727 — Assessment of the In Vivo Pharmacodynamic
    Profile of Ceftibuten/VNRX-7145 Combination against Serine
    β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine
    Thigh Infection Model.
    L.M. Avery, K. Abdelraouf, D.P. Nicolau.
  • SUNDAY – AAR-728 — Oral Bioavailability of Novel
    Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human
    Primates.
    D. Pevear, R. Trout, L. McLaughlin, J. Hamrick, G. Moeck.

Session P595
CPHM02 – Antimicrobial
Susceptibility Testing – Test Performance for New Agents

Poster
Presentation
Location: Exhibit and Poster Hall
11:00am –
1:00pm PT

  • SUNDAY – CPHM-860 — Impact of Variations in Susceptibility
    Testing Parameters on the In Vitro Activity of Ceftibuten in
    Combination with VNRX-7145.
    M. Hackel, D. Dressel, D. Sahm.

About VenatoRx Pharmaceuticals

VenatoRx is a private pharmaceutical company that is focused on the
discovery and development of novel anti-infectives to treat
multi-drug-resistant bacterial infections and hard-to-treat viral
infections. Founded in 2010, VenatoRx has built a world-class in-house
R&D organization that has filed over 100 patents spanning multiple
research programs. VenatoRx has received significant funding awards from
the National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health (NIH), Wellcome Trust, CARB-X, and the
Defense Threat Reduction Agency (DTRA) as well as private equity
investments from Versant Ventures, Abingworth, and Foresite Capital.

The Company’s most advanced development-stage product is VNRX-5133, an
injectable beta-lactamase inhibitor (BLI) that features selective and
potent in vitro activity against both serine- and
metallo-beta-lactamases, including ESBL, OXA, KPC, NDM, and VIM enzymes.
VenatoRx believes that VNRX-5133, in a fixed combination with the fourth
generation cephalosporin, cefepime, has the potential to provide a
valuable broad-spectrum treatment option to meet unmet medical need in
patients with infections due to carbapenem-resistant pathogens including
carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas
aeruginosa
(CRPA), suspected polymicrobial infections caused by both
gram-negative and gram-positive susceptible pathogens, and engineerable
MDR bioterror pathogens such as Burkholderia spp. and Salmonella
spp. Early clinical studies of cefepime/VNRX-5133 have been completed
and VenatoRx intends to initiate Phase 3 pivotal trials during the third
quarter 2019. This project has been funded in whole or in part with
Federal funds from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human
Services, under Contract No. HHSN272201300019C, and The Wellcome Trust
under Award No. 360G-Wellcome-101999/Z/13/Z.

VenatoRx’s second development-stage product in clinical development is
VNRX-7145, an orally bioavailable BLI that in a fixed combination with
the third generation orally bioavailable cephalosporin, ceftibuten, has
the potential to rescue activity of the partner antibiotic against ESBLs
and key carbapenem-resistant Enterobacteriaceae, including those
expressing KPC and OXA carbapenemases. This project has been funded in
part with Federal funds from the National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Department of Health
and Human Services, under Contract No. HHSN272201600029C.

Additionally, VenatoRx has a broad pipeline of preclinical programs
including a novel class of Penicillin-Binding Protein (PBP) inhibitors
that are impervious to beta-lactamase-driven resistance, and novel
antiviral agents targeting Hepatitis B Virus. For more information,
please visit www.venatorx.com.

Contacts

MEDIA CONTACT:
Heather Hunter
Vice President,
Communications
VenatoRx Pharmaceuticals, Inc.
[email protected]
610.644.8935
x8327

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.